Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; A systematic review and metaanalysis

Abstract

PurposeAlthough ultrasonography (US) is a standard technique for the assessment of cervical lymph node (LN) metastasis, the role of F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is increasingly reported. The purpose of this study is to assess the diagnostic accuracy of F-18 FDG PET-CT for detection of cervical LN metastasis in thyroid cancer (TCa) patients through a meta-analysis. Patients and methodsThe PubMed, Cochrane Database, and Embase from the earliest available date of indexing through September 31, 2019, were searched for studies evaluating the diagnostic performance of F-18 FDG PET-CT for detection of LN metastasis in TCa. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. ResultsAcross 9 studies (759 patients), the pooled sensitivity for F-18 FDG PET-CT for all cervical LN metastasis in TCa was 0.30 (95% CI; 0.26–0.35) a pooled specificity of 0.94. For central LN metastasis, the pooled sensitivity was 0.28 (95% CI; 0.21–0.34) and a pooled specificity was 0.87 (95% CI; 0.83–0.90). For lateral LN metastasis, the pooled sensitivity was 0.56 (95% CI; 0.50–0.62) and a pooled specificity was 0.94. ConclusionsF-18 FDG PET-CT shows a low sensitivity and high specificity for the detection of metastatic LNs in patients with TCa. The current data suggests that F-18 FDG PET-CT is not indicated in the work up of patients with thyroid cancer or biochemical evidence of recurrent disease.